On June 24, 2024, Teva announced the launch of an authorized generic for Victoza® (liraglutide injection 1.8mg).…

In September 2023, the FDA approved the subcutaneous (SC) administration of Entyvio® for the maintenance treatment of adults with moderately to severely active ulcerative colitis (UC). On April 18, 2024, the FDA expanded the approval of Takeda’s Entyvio® (vedolizumab) to include…

On April 16, 2024, the FDA approved Selarsdi (ustekinumab-aekn) for subcutaneous (SC) use as a biosimilar referencing Stelara (ustekinumab). Selarsdi is approved for only two of the indications that Stelara currently has approval for…

Following the lead of drug manufacturer Bohringer Ingelheim (BI), both AstraZeneca and GSK have announced that they will restrict the out-of-pocket (OOP) cost for all their inhaled drugs to $35 or less per month. AstraZeneca’s program, which begins on June 1, 2024, includes…

On February 23, 2024, the FDA approved Alvotech and Teva’s Simlandi (adalimumab-ryvk; formerly AVT02) injection, as an interchangeable biosimilar to high-concentration, citrate-free Humira. The high-concentration formulation accounts for…